FIGURE 2.

Model‐based exposure and ILD analysis. Proportion of patients with ILD events stratified by osimertinib AUC_ss quartiles (A) and visual predictive checks for the frequency of ILD events (B) and the predicted mean probability and observed proportion of patients with ILD events (C) in different populations. Simulation of the frequency of ILD events for patients treated with 0, 40, 80, or 160 mg osimertinib and patients treated with comparator therapy in different racial populations (D) and prediction of ILD events for patients according to line of therapy (E). AUC_ss, area under the curve at steady state; CI, confidence interval; EGFR‐TKI, epidermal growth factor receptor‐tyrosine kinase inhibitor; ILD, interstitial lung disease.